You are about to leave the Clinical Value website now.

Cancel

Liver

23 June 2023

Leading the Way for HCC Surveillance and Diagnosis: Prof. Henry LY Chan

In this video, Prof Henry LY Chan, Deputy Chief Manager at Union Hospital Hong Kong, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…

READ MORE
19 June 2023

Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis

This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.…

READ MORE
19 June 2023

The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data

The purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data. Li B, Liu A, Wen Y, Yang…

READ MORE
19 June 2023

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients

This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients. Xu F, Zhang L, He W,…

READ MORE
19 June 2023

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

This systematic review and meta-analysis of cohort studies of patients with cirrhosis aimed to evaluate the benefit and harms of HCC surveillance in patients with cirrhosis.…

READ MORE
19 June 2023

Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer

The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal…

READ MORE
19 April 2023

Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma

This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC. Bhatti ABHH, Naz K, Abbas G, Khan NY,…

READ MORE
12 April 2023

PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu

In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…

READ MORE
17 March 2023

Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region

A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and…

READ MORE
17 March 2023

Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis

This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…

READ MORE
17 March 2023

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…

READ MORE
14 March 2023

Biomarkers for the Early Detection of Hepatocellular Carcinoma

This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…

READ MORE
14 March 2023

Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China

This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…

READ MORE
14 March 2023

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

These latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.…

READ MORE
14 March 2023

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma

This study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its…

READ MORE
14 March 2023

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…

READ MORE
14 March 2023

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition), additional high-quality evidence has emerged with relevance to the diagnosis, staging,…

READ MORE
14 March 2023

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update

The 4th version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, and published in October 2017 in Japanese. New…

READ MORE
14 March 2023

Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis

Society guidelines differ in their recommendations for surveillance to detect early-stage hepatocellular carcinoma (HCC) in patients with cirrhosis. This study compared the performance of surveillance imaging,…

READ MORE
14 March 2023

Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature

HCC diagnosis can be particularly challenging in some cases and the obtained results seem ambiguous, resulting in a long-term and delayed diagnostic process.This paper presents three…

READ MORE
14 March 2023

Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma

This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…

READ MORE
14 March 2023

Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma

This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…

READ MORE
13 March 2023

Hepatocellular carcinoma surveillance: current practice and future directions

This review article provides a comprehensive overview of the indications and rationale for HCC surveillance, currently available surveillance methods and their utilization, effectiveness, and limitations, as…

READ MORE
13 March 2023

Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis

PIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of…

READ MORE
13 March 2023

Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA

This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…

READ MORE
13 March 2023

Leading the Way for HCC Surveillance and Diagnosis: Dr Bao Toan Nguyen

In this video, Dr Bao Toan Nguyen from MEDIC-LAB Ho Chi Minh discusses how PIVKA-II can complement AFP in assisting clinicians in the early detection and…

READ MORE
9 December 2022

Liver Disease in Asia Pacific: Insights from Prof Pierce Chow

In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…

READ MORE
9 December 2022

Liver Cancer in Japan: Dr Shun Kaneko on HCC Screening and Surveillance

Japan is a global leader in hepatocellular carcinoma (HCC) surveillance, with an effective programme that enables early-stage carcinomas detection. Yet unmet needs continue to affect the…

READ MORE
9 December 2022

The clinical utility of Elecsys GAAD score in the diagnosis of hepatocellular carcinoma

The performance of Elecsys® GAAD score, which includes the parameters of gender, age, alpha-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonists-II (PIVKA-II) in…

READ MORE
9 December 2022

Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This…

READ MORE
9 December 2022

Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study

This study systematically evaluates biomarkers mentioned in international guidelines and peer-reviewed literature for HCC surveillance and diagnosis, in order to identify combinations of biomarkers that display…

READ MORE
9 December 2022

Elecsys PIVKA-II and Elecsys AFP assays demonstrate good clinical performance for hepatocellular carcinoma (HCC) diagnosis across different disease stages and aetiologies

This study evaluates the clinical performance of the new Elecsys PIVKA-II immunoassay and the previously launched Elecsys AFP assay (Roche Diagnostics) to aid in the diagnosis…

READ MORE
9 December 2022

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify…

READ MORE
9 December 2022

Analytical performance and method comparison of the Elecsys PIVKA-II immunoassay as an aid in diagnosis of hepatocellular carcinoma (HCC)

This study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a…

READ MORE

Be the first to receive updates, event opportunities, and thought leadership insights.